Media

 

 

The Uveitis Podcast, hosted by Proctor alumni Dr. Jessica Shantha and Dr. Kareem Moussa from UC Davis, offers a comprehensive exploration of uveitis, featuring six episodes packed with invaluable insights from world-renowned specialists in the field.

In-depth, patient-focused interviews with leading uveitis experts cover a wide array of topics related to the diagnosis and treatment of this challenging condition.

The inaugural episode, "The Uveitis Podcast: Patient Education Preview," sets the stage for a series dedicated to providing patient-focused education on uveitis. Subsequent episodes delve into specific aspects of uveitis care, beginning with "Pediatric Uveitis: A Family Perspective," which features a heartfelt discussion with Justin and his mother Patrice about their experiences with pediatric uveitis. 
Listeners gain a fundamental understanding of uveitis in "What is Uveitis?" as Dr. Nisha Acharya from the F.I. Proctor Foundation at the University of California, San Francisco, elucidates the condition's nature, prevalence, and underlying causes. The podcast further explores the evaluation of uveitis patients in a conversation with Dr. John Gonzales, also from the F.I. Proctor Foundation. Dr. Eric Suhler from the Casey Eye Institute at Oregon Health & Science University sheds light on the role of systemic immunomodulatory therapy in managing noninfectious uveitis, while Drs. Sunil Srivastava and Steven Yeh discuss the use of local therapy in the management of the same condition, providing valuable insights from Cleveland Clinic's Cole Eye Institute and the Stanley M. Truhlsen Eye Institute at the University of Nebraska, respectively.
With a mix of expert interviews, patient perspectives, and educational content, The Uveitis Podcast offers a unique platform for healthcare professionals and patients alike to deepen their understanding of uveitic diseases and explore innovative approaches to their management.
© 2024 The Uveitis Podcast, Kareem Moussa, and Jessica Shantha

 

Episodes 

 

 

Jun 11, 2021

The Uveitis Podcast: Patient Education Preview

Welcome to The Uveitis Podcast: Patient Education. Join us as we discuss uveitis in a patient-focused approach.

 1 min

 

 

o   JUN 11, 2021

Pediatric Uveitis: A Family Perspective

Justin, diagnosed with uveitis since age 5, and his mother Patrice join Dr. Kareem Moussa to discuss their experience with pediatric uveitis.

43 min

 

JUN 11, 2021

 

What is Uveitis? with Dr. Nisha Acharya

Dr. Nisha Acharya from the F.I. Proctor Foundation at University of California, San Francisco, joins the podcast to explain what is uveitis, who gets it, and what causes it.

38 min

 

JUN 11, 2021

Evaluation of the Uveitis Patient with Dr. John Gonzales

Dr. John Gonzales from the F.I. Proctor Foundation at University of California, San Francisco discusses the evaluation of the uveitis patient.

29 min

 

=

JUN 11, 2021

Systemic Immunomodulatory Therapy with Dr. Eric Suhler

Dr. Eric Suhler from Casey Eye Institute at Oregon Health & Science University discusses the role of systemic immunomodulatory therapy in the management of noninfectious uveitis.

55 min

 

 

 

JUN 11, 2021

Local Therapy with Drs. Sunil Srivastava and Steven Yeh

Dr. Sunil Srivastava from Cleveland Clinic's Cole Eye Institute and Dr. Steven Yeh from the Stanley M. Truhlsen Eye Institute at the University of Nebraska discuss the role of local therapy in the management of noninfectious uveitis.

32 min

© 2024 The Uveitis Podcast Kareem Moussa and Jessica Shantha

 

 

 

 

 


AAO logo - Papale Eye Center

Media featuring

Nisha Acharya, MD, MS​

 

In the landscape of ophthalmology and epidemiology, Dr. Nisha Acharya stands as a beacon of excellence, renowned for her profound expertise and tireless dedication to advancing the understanding and treatment of ocular inflammatory diseases. Holding the distinguished Elizabeth C. Proctor Professorship at the University of California San Francisco, Dr. Acharya's contributions extend far beyond the confines of academia, profoundly impacting the lives of countless individuals afflicted by uveitis and related conditions.

With a clinical focus centered on uveitis and ocular inflammatory diseases, Dr. Acharya exemplifies the epitome of specialized care, offering patients not only expert diagnosis and treatment but also a compassionate understanding of the challenges they face. Her commitment to excellence is evident in every aspect of her work, from pioneering research endeavors to leading-edge clinical trials aimed at evaluating the efficacy of novel treatment modalities.

 

At the forefront of epidemiological research, Dr. Acharya's investigations into the prevalence and risk factors associated with ocular inflammatory conditions have shed invaluable light on these complex diseases, guiding clinical practice and public health initiatives alike. As Principal Investigator of the NIH-funded First-line Antimetabolites for Steroid-Sparing Treatment (FAST) Trial, she leads a multidisciplinary team in a groundbreaking endeavor to redefine the standard of care for uveitis patients nationwide.

Not content with mere innovation, Dr. Acharya is also instrumental in driving standardization efforts within the field, serving as a key figure in the Standardization of Uveitis Nomenclature working group. Her leadership role in the Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial underscores her unwavering commitment to rigorous scientific inquiry and evidence-based practice.

Beyond her scholarly pursuits, Dr. Acharya's influence extends to the highest echelons of professional societies, where she plays an integral role in shaping the future of ophthalmology. As a member of the executive committee of the American Uveitis Society and chair of the American Academy of Ophthalmology Knowledge Base Panel for Uveitis, she champions the dissemination of knowledge and best practices, ensuring that practitioners across the nation are equipped to deliver the highest standard of care to their patients.

 

Live at AAO 2022 with Dr. Nisha Acharya

OCT 27, 2022 by Nisha Acharya, MD, Andrew R Carey, Matthew Timothy Feng, Lorraine M Provencher, Rajesh C Rao, Edmund Tsui

Recorded in front of a live audience at the AAO 2022 Annual Meeting in Chicago, this episode features Dr. Nisha Acharya discussing her recent Ophthalmology arti... 

Audio and Podcasts / Podcast 

Preview of Uveitis Section at Retina Subspecialty Day 2023

NOV 03, 2023 by Arthi Ganesh Venkat, MD, Nisha Acharya

Dr. Nisha Acharya, one of the panelists on the Uveitis section at Retina Subspecialty Day, has a conversation with Dr. Arthi Venkat about topics to be discussed... 

Interviews / Interview 

Incidence of Herpes Zoster Ophthalmicus

APR 15, 2022 by Matthew Timothy Feng, MD, Edmund Tsui, Nisha Acharya

Dr. Matthew Feng is joined by co-host Dr. Edmund Tsui to discuss what's new in our understanding of zoster, vaccinations, and more with Dr. NishaAcharya from... 

Audio and Podcasts / Podcast 

Methotrexate vs. Mycophenolate for Noninfectious Uveitis

OCT 17, 2019 by Rahul N Khurana, MD, Nisha Acharya

In this interview from AAO 2019, Dr. NishaAcharya presents results from her NEI-funded trial comparing 2 commonly used, steroid-sparing, immunosuppressive drug... 

Interviews / Interview 

Episode 246: Uveitis Training and the FAST Study with Dr. Nisha Acharya

JUL 13, 2020 by Jayanth S Sridhar, MD, Nisha Acharya

Drs. Nisha Acharya joins the program to discuss results of the multicenter FAST study, comparing methotrexate and mycophenolate mofetil for noninfectious uveiti... 

Audio and Podcasts / PodcastCME

Global Ophthalmology Summit - Global Eye Health: The Future of Global Eye Research Collaboration

SEP 06, 2022 by Nisha Acharya, MD, Paisan Ruamviboonsuk, Gyan Prakash MBA PHD, Ido Didi Fabian, Carol L Shields

Global Eye Health: The Future of Global Eye Research Collaboration Presentation. Moderated by Drs. Nisha Acharya and Paisan Ruamviboonsuk with presentations 

Presentations / Presentation 

MERIT Trial Results: Intravitreal Therapy for Uveitic Macular Edema

NOV 09, 2023 by Edmund Tsui, MD, Nisha Acharya, Douglas A Jabs, MBA

Drs. Nisha R. Acharya and Douglas A. Jabs discuss landmark findings of the Macular Edema Ranibizumab versus Intravitreal Anti-inflammatory Therapy (MERIT) trial... 

Audio and Podcasts / Podcast 

AAO-AAPOS Journal Club June 2020 (AAPOS Pediatric Uveitis Committee Selections)

JUN 29, 2020 by Virginia Miraldi Utz, MD, Sheila Therese Angeles-Han MD MS, Nisha Acharya, Hatice N Sen

Dr. Utz moderates this virtual journal club with Drs. Angele-Han, Acharya, and Sen. Articles included: 2019 American College of Rheumatology/Arthritis Foundatio... 

Presentations / Presentation 

Barriers to DR Screening

MAR 01, 2024

Social determinants of health are linked with barriers to eye care among people with type 2 diabetes. 

EyeNet / Eyenet Article 

Fork in the Road: Deciding Which Uveitis Treatment is Best

FEB 13, 2024 by Christopher R Henry, MD, Ghazala A Datoo O'Keefe, Edmund Tsui, Nisha Acharya, Douglas A Jabs, MBA, Parisa Emami Naeini, Shilpa Kodati, Arjun B Sood

In this webinar, Drs. Acharya, Emami, Henry, Jabs, Kodati, O'Keefe, Sood, and Tsui, provide cases centered around four of the latest uveitis-related clinical... 

Presentations / Presentation

In the landscape of ophthalmology and epidemiology, Dr. Nisha Acharya stands as a beacon of excellence, renowned for her profound expertise and tireless dedication to advancing the understanding and treatment of ocular inflammatory diseases. Holding the distinguished Elizabeth C. Proctor Professorship at the University of California San Francisco, Dr. Acharya's contributions extend far beyond the confines of academia, profoundly impacting the lives of countless individuals afflicted by uveitis and related conditions.

With a clinical focus centered on uveitis and ocular inflammatory diseases, Dr. Acharya exemplifies the epitome of specialized care, offering patients not only expert diagnosis and treatment but also a compassionate understanding of the challenges they face. Her commitment to excellence is evident in every aspect of her work, from pioneering research endeavors to leading-edge clinical trials aimed at evaluating the efficacy of novel treatment modalities.